3D Medicines (Beijing) Co., Ltd.

Quick facts

Phase 2 pipeline

• 3D185 · Diabetes
  3D185 is a small molecule that targets the SGLT2 receptor.

Phase 1 pipeline

• Highly selective FGFR1-3 inhibitor

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• 3D Medicines (Beijing) Co., Ltd. portfolio CI brief
• 3D Medicines (Beijing) Co., Ltd. pipeline updates RSS